

Reference number(s)
2469-H

SPECIALTY QUANTITY LIMIT PROGRAM

CINQAIR (reslizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization. The recommended dosing parameters for the treatment of severe eosinophilic asthma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Cinqair 100 mg/10 mL (10 mg/mL) single-use vial	3 vials per 28 days	6 vials per 28 days	3 mg/kg once every 4 weeks

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Cinqair [package insert]. Frazer, PA: Teva Pharmaceuticals, Inc.; January 2019.